Aenova Group

Motivation, Innovation, and the Power of Collaboration

Leading the Way in Pharmaceutical Manufacturing by Fostering an Agile Mindset and an Inclusive Culture.

Aenova Launches Program to Accelerate Pharmaceutical Development

Aenova announces the launch of its Aenovation program. This initiative aims to accelerate the early development of pharmaceutical formulations.

The Evolution of the CDMO Industry

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Expert Statement: Neil Jones, Aenova

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Kühne Holding Acquires Aenova from BC Partners

Kühne Holding has agreed to purchase Aenova Group, a pharma contract development and manufacturing organization (CDMO), from BC Partners. BC will reinvest and retain a minority stake in Aenova. The financial terms remain undisclosed.

How CDMOs Can Contribute to Pharma Supply even Better

The demand for medicines is increasing rapidly and R&D pipelines have doubled over the last decade.

Aenova Appoints Hanno Scheffczik as Managing Director of its Marburg Site

Hanno Scheffczik has been appointed as the new Managing Director of Temmler Pharma, a member of the Aenova Group. Effective Mar. 1, 2023, he succeeds Alfred Veit, who is retiring.

Vaccine Filling at the Highest Level

Recent studies show that contract manufacturers for the pharmaceutical industry, so-called CDMOs (contract development and manufacturing organizations), have so far been little involved in the production of vaccines. This is changing with the outbreak of the Covid-19 pandemic.

Aenova Expands Production of Tablets with Highly Potent Oncology Drugs

Contract manufacturer Aenova has put a third, high-performance tablet press including integrated automatic in-process control into operation at its site in Regensburg, Germany, to expand its production capacity of highly potent oncology drugs.

Facing Strong Headwinds

So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.

Aenova Presents New Organizational Group Structure

New structure bundles the CDMO's production areas into the business units Solids, Semi Solids & Liquids and Soft Gel Capsules.

The Expanding Role of Contract Manufacturing

Standing Out in Global Pharmaceutical Contract Manufacturing Market

Swedish Drug Maker Recipharm Looks to List or Sell Stake

Bridgepoint to Sell Drugs Maker Aenova